• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
    • {%itemName%} {%arrowSpan%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      VENCLYXTO-based regimens: Give your patients the chance to break free from the burden of detectable disease and treatment

      Benefits patients and HCPs

      Hear Dr. George Follows discuss deep response with VENCLYXTO and how it benefits HCPs and R/R patients with CLL

      Aim for deep response and give your patient a chance to be treatment free

      Select a tab to reveal how the different VENCLYXTO combinations can benefit your patients

      *Deep response = Peripheral blood uMRD (tumour cell per 104 white cells; (ITT population)
      BR = bendamustine+rituximab; Clb+O = Chlorambucil + obinutuzumab; MRD = minimal residual disease; PFS = progression-free survival; Ven+O = VENCLYXTO + obinutuzumab; Ven+R = VENCLYXTO  + rituximab.


      Survival off treatment

      VENCLYXTO + rituximab: Deep responses could improve your patients’ overall chances of survival, off treatment4,6

      PFS analysis based on MRD status in peripheral blood at EoCT (VENCLYXTO + rituximab arm)4,6

      Adapted from Seymour JF, et al. 2019.
      Data cut-off: 8 May 2019. uMRD was evaluated using ASO-PCR and/or flow cytometry.
      ASO-PCR = allele-specific oligonucleotide polymerase chain reaction; EOCT = end of  combination  therapy; MRD = minimal residual disease; PFS  = progression-free survival; Ven+O = VENLCYXTO + obinutuzumab; Ven+R = VENCLYXTO + rituximab.


      BCL-2 inhibition

      VENCLYXTO has a unique MoA, giving patients a chance to achieve deep responses1,7

      VENCLYXTO selectively displaces pro-apoptotic proteins from BCL-2's and rapidly induces the process of apoptosis in CLL cells.7

      BCR's and BCL-2's work in different ways7,8

      BCR = B-cell receptor pathway; BCL-2 = B-cell lymphoma 2; BTK = Bruton's tyrosine kinase; uMRD = undetectable minimal residual disease.



      1. VENCLYXTO Summary of Product Characteristics.
      2. Seymour JF, et al. N Engl J Med 2018; 378(12): 1107–1120.
      3. Fischer K, et al. N Engl J Med 2019; 380: 2225-2236.
      4. Seymour JF, et al. ASH 2019; Oral presentations. Available  from: https://medically.roche.comen/search/pdfviewer.5a3b91f2-018e-4567-8cfc-3702f6da9ec5.html?cid=slpsxx1912haxxash2019  [accessed January 2020].
      5. Fischer K, et al. ASH 2019. Oral presentation.
      6. Seymour JF, et al. iwCLL 2019; Poster presentation #2266.
      7. Del Gaizo Moore  V, et al. J Clin Invest 2007; 117(1):112-21.
      8. Wiestner A. Haematologica. 2015; 100(12): 1495–1507.
      9. Stilgenbauer S, et al. Lancet Oncol 2016; 17: 768-778.



      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-VNCCLL-200348. Date of preparation: December 2020